An observational study in Primary Liver Cancers, sponsored by Chifeng Tumor Hospital. Not yet recruiting at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2025-10-08.
Sponsored by Chifeng Tumor Hospital · Observational
To fill in the "Brief Summary" field, you need to provide clear, easy-to-understand information about the study for patients, families, and healthcare providers. Here's a suggested summary:
This study compares the dosimetric features and clinical effects of body gamma knife and VMAT radiotherapy for locally advanced primary liver cancer. We retrospectively analyze 20 patients from Chifeng Tumor Hospital who cannot or refuse surgery. For each patient, we will develop both body gamma knife and VMAT radiotherapy plans. Then, we'll compare the dose distribution in the tumor target (including conformity index and homogeneity index) and the radiation exposure to organs at risk (such as the spinal cord, stomach, and liver). The goal is to find out which radiotherapy approach is more beneficial, so patients, families, and healthcare teams can better understand how this research supports treatment decisions.
Chifeng Tumor Hospital is the lead sponsor of 2 studies on the registry; 2 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Patients with locally advanced primary liver cancer (unsuitable for/refusing surgery, meeting inclusion \& not exclusion criteria), aged 18-75 years, from Chifeng Tumor Hospital.
Exclusion Criteria:
Patients in this group receive body gamma knife radiotherapy. The treatment utilizes fixed radiation sources, and the treatment couch moves to each treatment target. A 50% isodose curve covers at least 95% of the Planning Target Volume (PTV), and this modality is applied for radiotherapy of locally advanced primary liver cancer.
Patients in this group receive radiotherapy with an accelerator (applying VMAT technology). Based on the tumor's location and surrounding organs at risk, beam angles and the number of fields are selected. The prescription dose curve covers 95% of the Planning Target Volume (PTV), and this method is used for radiotherapy of locally advanced primary liver cancer.
Conformity Index Comparison: Body Gamma Knife vs. VMAT for Locally Advanced Primary Liver Cancer
Compare the conformity index (a dosimetric measure of how well radiation conforms to the target volume) between body gamma knife and VMAT radiotherapy in patients with locally advanced primary liver cancer.
Time frame: Within 1 month after completion of radiotherapy planning
Gradient Index Comparison: Body Gamma Knife vs. VMAT for Locally Advanced Primary Liver Cancer
Compare the gradient index (a dosimetric measure of dose fall-off outside the target volume) between body gamma knife and VMAT radiotherapy in patients with locally advanced primary liver cancer.
Time frame: Within 1 month after completion of radiotherapy planning
Homogeneity Index Comparison: Body Gamma Knife vs. VMAT for Locally Advanced Primary Liver Cancer
Compare the homogeneity index (a dosimetric measure of dose uniformity within the target volume) between body gamma knife and VMAT radiotherapy in patients with locally advanced primary liver cancer.
Time frame: Within 1 month after completion of radiotherapy planning
Liver V20 Comparison: Body Gamma Knife vs. VMAT for Locally Advanced Primary Liver Cancer
Compare the volume of liver receiving 20 Gy (V20) between body gamma knife and VMAT radiotherapy in patients with locally advanced primary liver cancer.
Time frame: Within 1 month after completion of radiotherapy planning
Liver Mean Dose (Dmean) Comparison: Body Gamma Knife vs. VMAT for Locally Advanced Primary Liver Cancer
Compare the mean dose (Dmean) to the liver between body gamma knife and VMAT radiotherapy in patients with locally advanced primary liver cancer.
Time frame: Within 1 month after completion of radiotherapy planning
Liver V5 Comparison: Body Gamma Knife vs. VMAT for Locally Advanced Primary Liver Cancer
Compare the volume of liver receiving 5 Gy (V5) between body gamma knife and VMAT radiotherapy in patients with locally advanced primary liver cancer.
Time frame: Within 1 month after completion of radiotherapy planning
Plan to share: Yes
Supporting information: Study protocol
No publications or documents are linked to this record.
This study is not yet recruiting, as verified in Sep 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Chifeng Tumor Hospital